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INCREASE OF THE BIOAVAILABILITY OF INTRAPERITONEAL ERYTHROPOIETIN
IN CHILDREN ON PERITONEAL DIALYSIS BY ADMINISTRATION IN
SMALL DIALYSIS BAGS
Roel E. Reddingius,1 Alberdina W. de Boer,1 Cornelis H. Schröder,1 Johannes L. Willems,2 
and Leo A.H. Monnens1
Department of Pediatrics,1 Department of Clinical Chemistry,2 St. Radboud University Hospital,
Nijmegen, The Netherlands
♦ Objective: To establish the effectivity of administra­
tion of erythropoietin intraperitoneally in a small amount 
of fluid in children with renal anemia on continuous 
ambulatory peritoneal dialysis (CAPD).
♦ Design: Prospective study in which children with renal 
anemia on CAPD were treated with erythropoietin intra­
peritoneally, administered in a specially designed bag 
containing 50 mL NaCI 0.9%.
♦ Setting: University hospital.
♦ Patients: The patient population consisted of 9 chil­
dren treated with CAPD and 1 treated with nightly inter­
mittent peritoneal dialysis. The median age was 7.8 years 
(range 4.1 -  15.2). Four of these children had not been 
treated with erythropoietin before (group A), and 6 had 
been treated with erythropoietin administered intra­
peritoneally in 250 mL of dialysis fluid (group B).
♦ Interventions: Patients in group A started on a dose of 
approximately 300 units/kg per week (group A). Patients 
in group B received their previous dose. Dosage was 
adjusted to achieve a target hemoglobin level of 6.5 -
7.0 mmol/L (1 04 - 112 g/L). Serum ferritin levels and 
transferrin saturation were monitored and iron supple­
mentation was prescribed in the case of iron deficiency.
♦ Main outcome measures: Weekly erythropoietin dose 
in relation to hemoglobin level.
♦ Resuits: In group A, median hemoglobin level rose 
from 5.3 mmol/L (85 g/L) to 6.6 mmol/L (106 g/L) after 6 
months of therapy, whereas the median erythropoietin 
dose decreased from 266 to 234 U/kg/week. In group B, 
hemoglobin levels remained stable and median erythro­
poietin dose decreased from 262 to 194 U/kg/week. One 
patient in this group, for unknown reasons, never re­
sponded to erythropoietin treatment. He was excluded 
from further analysis. In the remaining 5 patients the 
median cumulative erythropoietin dose was 3250 U/kg in 
the 3-month period prior to the start of the study and 2713 
in the 3-month period starting 6 months after the begin­
ning of the study. This difference of 17% was statistically 
significant using a Wilcoxon test (p < 0.05).
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♦ Conclusion: Intraperitoneal administration of erythro­
poietin in a small amount of dialysis fluid leads to a 
decrease in the required dose.
KEYWORDS: Children; erythropoietin; intraperi- 
toneal administration.
n children treated with continuous ambulatory 
peritoneal dialysis (CAPD) renal anemia can be 
effectively treated with erythropoietin adminis­
tered intraperitoneally (IP) (1), A major advan­
tage, as opposed to subcutaneous administration, 
is the avoidance of painful injections. A disadvan­
tage is the necessity of a higher dose, which is 
related to a lower biological availability. To maxi­
mize resorption, erythropoietin is usually admin­
istered in the smallest commercially available bag 
of 250 mL during a prolonged dwell (10 -  12 hours). 
In a previous study we compared the pharmaco­
kinetics of erythropoietin after subcutaneous and 
IP administration in children on CAPD (2). It was 
established tha t resorption after IP administra­
tion, measured as area under the curve, was simi­
lar to resorption after subcutaneous administra­
tion if erythropoietin was administered IP in 50 
mL of dialysate. In this article we present the 
results of a therapeutic study in which eryth­
ropoietin was administered this way, using a spe­
cially designed 50 mL bag.
PATIENTS AND M ETHODS
Children on CAPD or nightly intermittent peri­
toneal dialysis (NIPD) already treated with IP 
erythropoietin and those in whom erythropoietin 
therapy was started entered the study. The study 
was performed between October 1994 and December 
1995. Two patients were not eligible for further 
evaluation, one because no exact data were available 
on previous treatment with erythropoietin and the 
other because the hemoglobin levels were being main-
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tained higher than usual in this child, whose parents 
were Jehovah’s witnesses.
The study population consisted of 10 children (4 
girls, 6 boys). Nine children were treated with CAPD, 
1 with NIPD. The median age of these children was 7.8 
years (range 4,1 -15.2). Causes of renal failure were: 
renal dysplasia (2), posterior urethral valves, hemolytic 
uremic syndrome, congenital nephrotic syndrome, 
interstitial nephritis, focal glomerulosclerosis, anti- 
GBM (glomerular basement membrane) glomerulo­
nephritis, hereditary acro-osteolysis, and unknown. 
The children had been treated with CAPD for a me-
dian period of 14 months (range 0 0).
Four children (group A) had had no previous 
treatment with erythropoietin. Median hemoglobin 
level was 5.3 mmol/L (range 4.3 -  5,7) [85 g/L (range 
68-  91)] in this group. Hemoglobin levels for chil­
dren without end-stage renal disease ranged be­
tween 7.1 mmol/L (114 g/L) and 9.0 mmol/L(144 g/L)
in our laboratory. In the children of group A, eryth­
ropoietin was started at a dose of approximately 300 
units per kilogram per week, administered 3 times 
per week.
Six children (group B) had been treated previously 
with erythropoietin, administered IP in the smallest 
commercially available bag (250 mL). These patients 
had been on erythropoietin for a median period of 28 
months (range 7 -  65). Their median hemoglobin 
level was 6.6 mmol/L (range 4.5 -7.3) [106 g/L(range 
72 -  117)] at the start of the study. Median erythro­
poietin dosage was 262 U/kg/week (range 154 -  545) 
in these patients when they entered the study. Five 
of 6 patients received erythropoietin 3 times per 
week, whereas one of them was on a twice-a-week 
schedule. Dose and schedule were not changed when 
these patients entered the study.
Erythropoietin (Recormon, Boehringer Mannheim 
GmbH, Almere, The Netherlands) was administered 
in dialysis bags which were specially made for this 
purpose (Baxter BV, Utrecht, The Netherlands). 
These bags contained 50 mL NaCl 0.9% solution. The 
parents injected erythropoietin into the bags them­
selves; they were carefully trained to do this by a 
member of the nursing staff. The bags, equipped with 
a UV-flash port, were instilled after complete drain­
age of the abdomen for a 10- to 12-hour dwell. In 
patients on CAPD erythropoietin was administered 
overnight, while this was done during the day in the 
patient on NIPD.
The target hemoglobin level was 6.5 -  7.0 mmol/L 
(104 -1 1 2  g/L) in both groups. Dosage was adjusted 
every 2 months. As long as the target level was not 
reached erythropoietin dosage was increased by 75 U/ 
kg/week. Dosage was decreased by 75 U if the 
hemoglobin concentration exceeded 7.0 mmol/L 
(112 g/L). Hemoglobin, hematocrit, and the number
of reticulocytes were assessed every 2 weeks. Serum 
ferritin levels and transferrin saturation were as­
sessed every 2 months, and iron supplementation 
was prescribed if there was evidence of iron defi­
ciency (serum ferritin below 100 |Hg/L; transferrin 
saturation below 20%).
RESULTS
In group A, 2 children were treated for a period of
7 months, while 2 were treated for a period of 11 
months. In all patients hemoglobin levels increased 
after the start of therapy. The median hemoglobin 
level after 6 months was 6.6 mmol/L (range 6.2 -  7.5) 
[106 g/L (range 99 -  120)]. No blood transfusions 
were needed. In the 2 patients who remained on 
therapy for 11 months, final hemoglobin levels were
8.0 mmol/L (128 g/L) and 8.1 mmol/L (130 g/L). The 
median starting dose was 266 U/kg/week (range 235 -  
293). After 6 months of therapy the median dose was 
reduced to 234 U/kg/week (range 100 -  294). The 
final dose was 238 and 176 U/kg/week in the 2 pa­
tients who remained on therapy for 11 months.
In group B, children were treated for a median 
period of 11 months (range 6 *- 12). Hemoglobin 
levels remained stable during the study (Figure 1). 
The median hemoglobin level was 6.8 mmol/L (range 
5.8 -  7,9) [109 g/L (range 93 -  126)] 6 months after
the start of the study. Erythropoietin dosage and 
range is given in Figure 2. The median dosage was 
262 U/kg/week at the start of the study and 194 after
6 months of therapy.
The range of erythropoietin dose was very broad. 
This was mainly due to a very high dosage of 545 U/ 
kg/week in 1 patient. This patient had started on 
erythropoietin 7 months prior to the start of the study 
and never reached satisfactory control of renal anemia, 
in spite of a high dose. This child was the only one to 
receive blood transfusions during the study period 
(Figure 1). He received a kidney transplant 6 months 
after entering the study. This patient seemed to be 
resistant to erythropoietin therapy; an explanation 
for this was not found. There was no iron deficiency 
(serum ferritin >1000 |ig/L), folic acid levels were
within the normal limits, and there was no reason to
/  t
assume that the patient suffered from infections.
The patient described above was excluded from 
the following statistical analysis because it is im­
possible to compare two modes of erythropoietin
a
administration in a patient who does not respond 
to the drug and who receives blood transfusions. 
Erythropoietin dosage was stable in the months 
prior to the start of the study and was stabilized 
again 6 months after the start of the study in the 
other 5 patients. The cumulative dose from T-2 to 
TO (the 3-month period before the start of the
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Figure 1 — Hemoglobin levels of the patients in group B. TO 
indicates the start of the study. The target hemoglobin level 
of 6 .5 -  7.0 mmol/L (104- 112 g/L) is indicated by the 
shaded area. A blood transfusion is indicated with an 
asterisk.
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Figure 2 — Minimum, median, and maximum erythropoietin 
dosage in group B. TO indicates the start of the study. 
N = number of patients studied.
study) as well as the area under the curve from T7 
to T9 (the 3-month period after reaching a stable 
erythropoietin dose) was calculated in these pa­
tients. Median cumulative dose for a 3-month pe­
riod decreased from 3250 U/kg (range 2002 -  5577) 
to 2713 (1690 -  3393). The cumulative dose de­
creased in all patients. The median decrease in the 
cumulative dose was 17% (range 5 -  45). The dif­
ference between the cumulative dose before and 
after the switch to erythropoietin administration 
in a small dialysate volume was statistically sig­
nificant (Wilcoxon; p < 0.05).
In patients treated with CAPD, renal anemia can 
be effectively treated with erythropoietin. Two modes 
of administration have been used successfully, sub­
cutaneous administration and IP administration.
Studies in adults have demonstrated that subcu­
taneous administration is very effective, with doses 
of 100 to 150 U/kg/week (3,4). In children, a mean 
maintenance dose between 74 and 210 U/kg/week 
has been reported (5-11). In children there seems to 
be an influence of age on the dosage needed, with 
younger children needing a higher dose (12).
Intraperitoneal administration has proven to be 
an alternative method of treatment. The major ad­
vantage of this mode of treatm ent is the fact that 
there is no need for painful injections. The major 
disadvantage is the higher maintenance dose. In a 
study in adults the mean maintenance dose was 
225 -  255 U/kg/week (13). Our group has reported a 
mean maintenance dose of 279 U/kg/week in a group 
of 16 children on CAPD (1). In this study eryth­
ropoietin was added to the smallest commercially 
available bag containing 250 mL dialysis fluid. Lower 
doses of 100 -  150 U/kg/week were reported in a 
small group of 3 children, 2 of whom received 
erythropoietin in a small volume of only 20 mL (14).
Biological availability is determined by the amount 
of dialysis fluid to which erythropoietin is added (15). 
We established that the resorption of erythropoietin 
after IP administration, measured as area under the 
curve, is similar to resorption after subcutaneous 
administration if erythropoietin is added to a small 
volume of only 50 mL of dialysate (2).
In the present study, 10 children were treated 
with eiythropoietin administered IP in such a small 
volume. In 4 childi'en who had not been previously 
treated with erythropoietin, the median dosage was 
234 U/kg/week after 6 months of therapy. In 6 chil­
dren who had been treated with erythropoietin IP in 
250 mL of dialysis fluid, the median dosage could be 
decreased from 262 to 194 U/kg/week.
These data are consistent with the hypothesis that 
the administration of erythropoietin in a small vol­
ume will lead to increased resorption and a decrease 
in the dose. Decreasing dialysis volume to 50 mL 3 
times per week dviring the night will lead to the 
absence of dialysis during these periods. During the 
period in which the study was performed, another 
study was done looking at weekly Kt/V a n d  creatinine 
clearance (16). In a group of 19 children a mean Kt/V 
of 2.31 was found, which is higher than values re­
ported for most adult groups. Since target values for 
Kt/V are not yet clearly defined for children, Kt/V 
cannot be used to establish, in the individual patient, 
whether or not a decrease in dialysis is possible.
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During this study we did not see clinical problems as 
a result of the decrease in dialysis volume. If we had, 
NIPD, with administration of erythropoietin during 
the day, may have been a solution.
Administration of erythropoietin once-a-week in­
stead of 3 times per week is probably not the right 
way to increase dialysis, We performed a study in 6 
children who had been successfully treated with 
erythropoietin IP, added to 250 mL of dialysis fluid, 
3 times per week (17)* In these children, erythropoietin 
was administered in the same weekly dose, once-a- 
week instead of 3 times per week. This was not 
effective, since hemoglobin levels started to decrease 
rapidly.
Contamination is a risk if medication is added to 
the dialysis fluid. During our previous study, in 
which erythropoietin was given IP added to a bag 
containing 250 mL of dialysis fluid, we saw one peri­
tonitis episode every 14.7 patient-months. In 1995, 
the year in which the present study was performed, 
the peritonitis incidence was once every 12.6 patient- 
months, which is within the expected variation.
It can be concluded that intraperitoneal adminis­
tration of erythropoietin in a small amount of dialy- 
sis fluid leads to a decrease in the required dose.
Although the observed decrease in dose does seem 
real, the question remains whether it is clinically 
significant. A median decrease of 17% in the need for 
erythropoietin was established. Although this does 
not seem much in terms of percentage, savings can 
amount to significant sums if it can be applied on 
expensive drugs such as erythropoietin. The com­
mercial pi'oduction of small bags for the purpose of 
drug administration may become even more interest­
ing if other drugs such as growth hormone become 
available for IP administration.
ACKNOW LEDGMENTS
Baxter Nederland B.V. is gratefully acknowledged for the 
production and supply of UV-flash compatible dialysate 
bags containing 50 mL 0.9% NaCL
REFERENCES
1. Reddingius RE, Schröder CH, Monnens LAH. 
Intraperitoneal administration of erythropoietin in 
children on CAPD. Eur J  Pediatr 1992; 151:540-2.
2. Reddingius RE, Schröder CH, Koster AM, Monnens 
LAH. Pharmacokinetics of recombinant human 
erythropoietin in children treated with continuous 
ambulatory peritoneal dialysis. Eur J  Pediatr 1994;
153:850-4.
3. Besarab A. Optimizing epoetin therapy in end-stage 
renal disease: the case for subcutaneous administra­
tion. Am J  Kidney Dis 1993; 22(Suppl l):13-22.
6.
7.
8 .
9.
10.
4, Korbet SM. Anemia and erythropoietin in hemodialysis 
and continuous ambulatory peritoneal dialysis. K id ­
ney Int 1993; 43(Suppl 40):S111-19.
5. Aufricht C, Balzar E, Steger H, et al. Subcutaneous 
recombinant human erythropoietin in children with 
renal anemia on continuous ambulatory peritoneal 
dialysis. Acta Paediatr 1993; 82:959-62.
Goldraich I, Goldraich N. Once weekly subcutaneous 
administration of recombinant erythropoietin in chil­
dren treated with CAPD. In: Khanna R, Nolph KD, 
Prowant BF, Twardowski ZJ, Oreopoulos DG, eds. 
Advances in peritoneal dialysis, Toronto: Peritoneal 
Dialysis Bulletin, 1992; 8:440-3,
Montini G, Zacchello G, Perfumo F et al. Pharma­
cokinetics and hematologic response to subcutaneous 
administration of recombinant human erythropoietin 
in children undergoing long-term peritoneal dialysis: 
A multicenter study. J  Pediatr 1993; 122:297-302. 
Ongkinco JR, Ruley EJ, Turner ME, Fragale MR. 
Efficacy of once- versus thrice-weekly subcutaneous 
recombinant human erythropoietin in children receiv­
ing continuous cycling peritoneal dialysis A m  JNephrol 
1994; 14:14-18.
Schärer K, Klare B, Braun A, Dressei P, Gretz N. 
Treatment of renal anemia by subcutaneous erythro­
poietin in children with preterminal renal failure.Acta  
Paediatr 1993; 82:953-8.
Sinai-Trieman L, Salusky IB, Fine RN. Use of subcu­
taneous recombinant human erythropoietin therapy 
in children undergoing continuous cycling peritoneal
dialysis. J  Pediatr 1989; 114:550-4.
Warady BA, Sabath RJ, Smith CA, Alon U, Hellerstein
S. Recombinant human erythropoietin in pediatric 
patients receivinglong-term peritoneal dialysis .Pediatr
Nephrol 1991; 5:718-23.
Scigalla P. Effect of re comb inant human erythropoietin 
treatment on renal anemia and body growth of chil­
dren with end stage renal disease. In: Gurland HJ, 
Moran J, Samtleben W, Scigalla P, Wieczorek L, eds. 
Erythropoietin in renal and non-r enal anemias. Contrib 
Nephrol 1991; 88:201-11.
Frenken LAM, Struijk DG, Coppens PJW, Tiggeler 
RGWL, Krediet RT, Koene RAP. Intraperitoneal ad­
ministration of recombinant human erythropoietin. 
Pent Dial h it  1992; 12:378-83.
Steele BT, Vigneux A. Intraperitoneal erythropoietin 
treatment of children with chronic renal failure i  ’ediatr
Nephrol 1995; 9:359-60.
Bargman JM, Jones JE, Petro JM. The pharma­
cokinetics of intraperitoneal erythropoietin adminis­
tered undiluted or diluted in dialysate. Per it D i d  Int 
1992; 12:369-72.
Walk TLM, Schröder CH, Reddingius RE, Lelive;t M, 
Monnens LAH, Willems JL. Adequate dialysis? Meas­
urement of Kt/V in a pediatric peritoneal dialysis 
population. Perit Dial Int 1997; 17:175-8,
Reddingius RE, Schröder CH, Monnens LAH. Intra- 
peritoneal administration of erythropoietin: once a 
week instead of three times per week (Abstract). 
Nephrol Dial Transplant 1993; 8:280A.
11.
12.
13.
14.
15.
16.
17.
470
